scholarly article | Q13442814 |
P356 | DOI | 10.3747/CO.V17I5.592 |
P953 | full work available at URL | http://www.current-oncology.com/index.php/oncology/article/download/592/514 |
https://europepmc.org/articles/PMC2949362 | ||
https://europepmc.org/articles/PMC2949362?pdf=render | ||
https://www.mdpi.com/1718-7729/17/5/592/pdf | ||
P932 | PMC publication ID | 2949362 |
P698 | PubMed publication ID | 20975873 |
P5875 | ResearchGate publication ID | 47545259 |
P50 | author | George Dranitsaris | Q92696583 |
P2093 | author name string | J. Edwards | |
R. Abbott | |||
S. Edwards | |||
M. Leblanc | |||
P2860 | cites work | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 |
Underrepresentation of patients 65 years of age or older in cancer-treatment trials | Q73311140 | ||
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool | Q79802528 | ||
Participation in cancer clinical trials: race-, sex-, and age-based disparities | Q80179103 | ||
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer | Q28186303 | ||
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action | Q33561213 | ||
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
Diagnosis and initial treatment of venous thromboembolism in patients with cancer | Q37593813 | ||
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial | Q44921373 | ||
Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis | Q45198180 | ||
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun | Q45309210 | ||
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy | Q46408279 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | colorectal cancer | Q188874 |
bevacizumab | Q413299 | ||
chemotherapy | Q974135 | ||
FOLFIRI | Q1389369 | ||
metastatic colon cancer | Q108566365 | ||
P304 | page(s) | 12-16 | |
P577 | publication date | 2010-10-01 | |
P1433 | published in | Current Oncology | Q3498968 |
P1476 | title | Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador | |
Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador | |||
P478 | volume | 17 |
Q33982704 | Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer |
Q35230910 | Methyl tert butyl ether is anti-angiogenic in both in vitro and in vivo mammalian model systems |
Q35230207 | Methyl tert butyl ether targets developing vasculature in zebrafish (Danio rerio) embryos |
Q41472249 | Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients |
Q45735669 | Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort |
Search more.